person · Reporting owner
McNealey Jennifer Isacoff
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Telesis Bio Inc.DNAY · Entity 15606 | Chief Financial Officer | February 27, 2022 | March 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Telesis Bio Inc.
Report date February 27, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.20 · Expires 2032-02-27 | Direct | 107,300 |
Reported balance
After 2022-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-27 · Grant · Acquired 107,300 · Balance 107,300 F1: The exercise price is the closing price of the Issuer's Common stock on February 28, 2022, the first business day following the date of grant. F2: Subject to the Reporting Person's continuing as a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest in equal monthly installments on the same day of the month as the Vesting Commencement Date. "Vesting Commencement Date" shall mean February 27, 2022 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 28,000 |
Reported balance
After 2022-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-27 · Grant · Acquired 28,000 · Balance 28,000 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4: Subject to the Reporting Person's continuing as a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, twenty-five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the remaining RSUs subject to the award shall vest in equal annual installments on the same day of the month as the Vesting Commencement Date. "Vesting Commencement Date" shall mean February 27, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is the closing price of the Issuer's Common stock on February 28, 2022, the first business day following the date of grant.
F2: Subject to the Reporting Person's continuing as a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest in equal monthly installments on the same day of the month as the Vesting Commencement Date. "Vesting Commencement Date" shall mean February 27, 2022
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F4: Subject to the Reporting Person's continuing as a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, twenty-five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the remaining RSUs subject to the award shall vest in equal annual installments on the same day of the month as the Vesting Commencement Date. "Vesting Commencement Date" shall mean February 27, 2022.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CDT Equity Inc.
Report date May 13, 2024 · Filed May 15, 2024
Section 16 reporting ended · disclosed 2024-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2033-11-30 | Direct | 0 |
Reported balance
After 2024-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-13 · Disposition to issuer · Disposed 65,000 · Balance 0 F1: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan. F2: The stock options were granted with a ten-year term and vest 33.3% on each of the first three anniversaries of the vesting commencement date, which is September 22, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan.
F2: The stock options were granted with a ten-year term and vest 33.3% on each of the first three anniversaries of the vesting commencement date, which is September 22, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2024 Filed May 15, 2024 20:30 UTC | CDT Equity Inc. CDT · Entity 1035 | Disposition to issuerStock Option (Right to Buy) · Derivative | 65,000 | $5.51 Strike: $5.51 | $358,150.00 |
DisclosureSEC source: 0001493152-24-019926 · ownership.xml · derivative · entry 1 McNealey Jennifer Isacoff · CIK 0001588132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2033-11-30 F1 · security: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan. F2 · derivative.exercise_date: The stock options were granted with a ten-year term and vest 33.3% on each of the first three anniversaries of the vesting commencement date, which is September 22, 2023. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 22:20 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $5.51 Strike: $5.51 | $358,150.00 |
DisclosureSEC source: 0001493152-23-043748 · ownership.xml · derivative · entry 1 McNealey Jennifer Isacoff · CIK 0001588132 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-11-30 F1 · security: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan. F2 · derivative.exercise_date: The stock options were granted with a ten-year term and vest 33.3% on each of the first three anniversaries of the vesting commencement date, which is September 22, 2023. Read SEC document |
| February 27, 2022 Filed Mar 1, 2022 16:30 UTC | Telesis Bio Inc. DNAY · Entity 15606 | GrantRestricted Stock Unit · Derivative | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001850079-22-000015 · wf-form4_164617020703432.xml · derivative · entry 2 McNealey Jennifer Isacoff · CIK 0001588132 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, twenty-five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the remaining RSUs subject to the award shall vest in equal annual installments on the same day of the month as the Vesting Commencement Date. "Vesting Commencement Date" shall mean February 27, 2022. F4 · derivative.expiration_date: Subject to the Reporting Person's continuing as a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, twenty-five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the remaining RSUs subject to the award shall vest in equal annual installments on the same day of the month as the Vesting Commencement Date. "Vesting Commencement Date" shall mean February 27, 2022. Read SEC document |
| February 27, 2022 Filed Mar 1, 2022 16:30 UTC | Telesis Bio Inc. DNAY · Entity 15606 | GrantStock Option (right to buy) · Derivative | 107,300 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001850079-22-000015 · wf-form4_164617020703432.xml · derivative · entry 1 McNealey Jennifer Isacoff · CIK 0001588132 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,300 Underlying: Common Stock · 107,300 shares Expires 2032-02-27 F1 · derivative.exercise_price: The exercise price is the closing price of the Issuer's Common stock on February 28, 2022, the first business day following the date of grant. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest in equal monthly installments on the same day of the month as the Vesting Commencement Date. "Vesting Commencement Date" shall mean February 27, 2022 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.